{
    "id": 6428,
    "fullName": "SMO H231R",
    "impact": "missense",
    "proteinEffect": "no effect - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SMO H231R lies within the ligand-binding pocket of the Smo protein (PMID: 25759020). H231R is predicted to have no effect on Smo protein function as demonstrated by the lack of increased basal Hedgehog (Hh) pathway signaling in cell culture, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759020).",
            "references": [
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "H231R",
    "createDate": "05/19/2015",
    "updateDate": "09/24/2019",
    "referenceTranscriptCoordinates": {
        "id": 123186,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129205357A>G",
        "cDna": "c.692A>G",
        "protein": "p.H231R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2204,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing SMO H231R was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).",
            "molecularProfile": {
                "id": 6278,
                "profileName": "SMO H231R"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6278,
            "profileName": "SMO H231R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123186,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129205357A>G",
            "cDna": "c.692A>G",
            "protein": "p.H231R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 123187,
            "transcript": "XM_011516522",
            "gDna": "chr7:g.129206311A>G",
            "cDna": "c.692A>G",
            "protein": "p.H231R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}